Ovarian and Breast Cancers
Cancer Type
Tumor Tissue (FFPE)
Sample Type
10 Working Days
Turnaround Time ¹
ACTHRD™ detects HRD status by LOH score and 24 HRR-related genes to evaluate whether a tumor is suitable for PARP inhibitors.
Precision Medicine to Plan Better Treatment
Every cancer is associated with a unique combination of genomic changes. Furthermore, different cells within a tumor may harbor different genomic abnormalities. Comprehensive genomic profiling can identify such changes in cell signaling pathways by detecting prognostic and predictive biomarkers. This information can then be used to facilitate treatment decisions. This process is known as precision medicine.
Why ACT Genomics?
Humane Process
Avoids multiple biopsies and the time cost associated with single-gene testing, as only a small specimen is required for the simultaneous detection of BRCA1/2.
Ideal Treatment
Evaluates use of PARP inhibitor.
Smart Budgeting
Evaluates options before treatment, according to genomic information, to ensure success rate and avoid wasting of funds.
Learn More
Can PARP Inhibitors Destroy My Cancer?
As the name suggests, precision medicine does away with much of the hardships associated with untargeted treatments. PARP Inhibitors are one example of how a patient can overcome treatment difficulties less painfully by targeting the vulnerable part of a cancer cell - its' DNA repair functions. Once the DNA repair mechanism of a cancer cell has some gene defects, such as BRCA and other HRR genes, and a homologous recombination deficiency (HRD) is formed, it's time for PARP inhibitors to clean up the mess. An effective and oral dose makes cancer treatment easy, and ovarian and HER2-negative breast cancer patients who previously suffered from the pain of multiple surgeries and ineffective chemotherapies can turn the tables on their fight against cancer.
Common Problems Associated with Cancer Treatment
- Chemotherapy and surgery are the only options recommended by the NCCN guidelines or single-gene testing results
- Complications and metastases make it difficult to determine an appropriate drug
- Ineffective treatment and cancer relapse after targeted therapy
More Comprehensive Diagnostic Solutions Than Traditional BRCA Gene Testing
Through Next Generation Sequencing (NGS), ACTHRD™ decodes BRCA1/2 cancer genes to map drug options based on thorough clinical research and is not limited to a single clinical treatment guideline. ACTHRD™ determines the growth mechanism on a genomic level to provide more treatment strategy options with a higher success rate.
ACTHRD™ is suitable for ovarian and breast cancers. As single gene testing only provides very limited results, NGS genomic profiling can detect any special genomic mutations to result in a more effective treatment.
.png)
Who Is Suitable for ACTHRD™?
- Considering PARP inhibitor treatment
- Newly diagnosed, advanced, recurrent and metastatic cancer
Documentation
Disclaimers / Footnotes
- Turnaround time starts from the date of receipt of approved samples at our CAP-accredited laboratory.
- Venkitaraman AR. (2009) Annu Rev Pathol.4:461-487.
- Lord CJ. et al. (2017) Science. 355(6330):1152-1158.
- O'Malley DM. et al. (2018) Mol Cancer Ther. 17(1 Suppl): Abstract no. LB-A12.
- da Cunha Colombo Bonadio RR. et al. (2018)Clinics(Sao Paulo). Aug 20;73(suppl 1):e450s.
